Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Obstructive sleep apnea (OSA) stands as an autonomous risk factor for a broad spectrum of cardiovascular diseases, particularly atrial fibrillation (AF), which is closely associated with heightened ...

Binge drinking and possibly, moderate alcohol intake, may trigger atrial fibrillation. Caffeine intake does not appear to be a trigger; although, some doctors still recommend that patients with atrial ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...

6 Table. Safety Profiles of Select Medications for SVT Adenosine Transient AV block, chest pain, flushing, dyspnea, hypotension, atrial fibrillation if preexcitation is present, PVCs, ventricular ...

That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to ...

Although percentages differed in ischemic cardiomyopathy and prior history of Afib, the differences between the two groups were not statistically significant. Among the 90 patients with LVSD in ...

Correspondence to Professor Paulus Kirchhof, Institute of Cardiovascular Sciences, University of Birmingham, Wolfson Drive, Birmingham, B15 2TT, UK; p.kirchhof{at}bham.ac.uk rhythm control therapy in ...

Atrial fibrillation is a cardiac arrhythmia in which the upper chambers of the heart the atria beat irregularly and, often, rapidly. The condition occurs as a consequence of uncoordinated ...

Catheter ablation is one of the most effective rhythm-control strategies for atrial fibrillation (AF). Conventional catheter ablation is performed using thermo-energy sources via either radiofrequency ...

CARDAMYST for Paroxysmal Supraventricular Tachycardia FDA Prescription Drug ... with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT ...